CYKLX
LaunchNDAOPHTHALMICSOLUTION/DROPS
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 27m ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYKLX is an ophthalmic solution of articaine hydrochloride, a local anesthetic approved in August 2025 for use in eye procedures. It is administered as drops directly to the ocular surface to provide topical anesthesia. The drug works by blocking sodium channels in nerve fibers, reversibly inhibiting pain signal transmission.
Launch12.6 years to LOE
Early-stage launch phase with zero competitive pressure creates significant opportunity for commercial team expansion and market-share capture.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYKLX launch presents a unique career opportunity in commercial leadership and go-to-market strategy, with 12 linked positions reflecting early-stage scaling. The uncontested market and 14-year patent window offer stability for professionals building careers in specialty ophthalmic commercialization.
Director/Director Business DevelopmentBusiness Development Lead
Worked on CYKLX at Genomics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.